Published in Health and Medicine Week, July 11th, 2005
According to research from Italy, "the aim of this study is to verify the efficacy and safety of pegylated (peg)-interferon alfa-2b in combination with ribavirin for initial treatment of hepatitis C virus (HCV)-associated mixed cryoglobulinemia. Eighteen patients (7 women and 11 men) affected by mixed cryoglobulinemia were included in the study and treated with peg-interferon alfa-2b 1.0 mcg/kg once a week plus ribavirin (1000 mg daily) for 48 weeks, regardless of the HCV genotype."
"At the end of the treatment HCV-RNA became undetectable in 15 patients (83%) and most patients...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week